Fibre Extrusion Technology Ltd (FET) has announced the launch of its FET-500 Series gel spinning systems, marking a major leap forward in the research and development of ultra-high-molecular-weight polyethylene (UHMWPE) fibres. This innovative platform is set to transform how biomedical and technical fibres are designed, tested, and produced on a laboratory and pilot scale.
A Game Changer for the Biomedical Fibre Market
FET, based in Leeds, has long been recognised as a pioneer in medical fibre extrusion technology, providing bespoke equipment for producing resorbable and non-absorbable sutures and other high-performance medical products. The company’s latest innovation, the FET-500, addresses a critical gap in the UHMWPE market — enabling flexible, small-scale R&D production in a sector traditionally dominated by large-scale, rigid manufacturing processes.
UHMWPE fibres are prized for their exceptional strength, low weight, and biocompatibility, making them ideal for orthopaedic implants, surgical sutures, and high-performance textiles. However, innovation in the sector has been constrained by complex processing and environmentally harmful solvents.
Sustainable Innovation with Supercritical CO₂ Technology
At the heart of the FET-500’s breakthrough is its patent-pending gel spinning process, which uses supercritical carbon dioxide (CO₂) as a green solvent instead of toxic chemicals like hexane or dichloromethane (DCM). This approach allows for the extraction of carrier oils and fibre washing without producing hazardous waste — a milestone in sustainable fibre processing.
Key benefits of the CO₂-based process include:
- Elimination of toxic solvents such as hexane and DCM
- Comprehensive oil recovery and recycling with zero solvent waste
- Up to 80% reduction in factory footprint compared to conventional systems
- Lower operational costs and a safer, cleaner working environment
- Plug-and-play scalability, adaptable to customer needs
This compact and energy-efficient batch washing system not only reduces environmental impact but also enhances fibre performance consistency, making it ideal for biomedical R&D and advanced material innovation.
From Concept to Commercialization
FET’s Fibre Development Centre in Leeds plays a central role in supporting clients through product development, process optimization, and demonstration trials. Equipped with a full FET-500 demonstration line, the facility allows researchers and manufacturers to test, validate, and scale new fibre formulations from concept to production readiness.
“The FET-500 is designed to unlock new levels of flexibility and sustainability in UHMWPE fibre development,” said an FET spokesperson. “By integrating supercritical CO₂ technology, we’re giving researchers and manufacturers the tools to innovate safely, efficiently, and responsibly.”
With the FET-500 Series, Fibre Extrusion Technology Ltd reinforces its position as a global leader in advanced fibre extrusion systems, offering the biomedical and technical textile sectors a new generation of clean, scalable, and high-performance solutions.
